沙库巴曲缬沙坦钠片联合螺内酯对慢性心力衰竭患者氧化应激及血管内皮功能的影响

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Sacubatril Valsartan Sodium Tablets combined with Spironolactone on chronic heart failure (CHF).Methods A total of 80 CHF patients who were treated in Shangrao People′s Hospital from April 2017 to November 2019 were selected as the research objects and divided into the control group and the observation group according to random number table method, with 40 cases in each group.The control group was treated with Spironolactone, and the observation group was treated with Sacubatril Valsartan Sodium Tablets combined with Spironolactone.The clinical effect, cardiac function, oxidative stress, vascular endothelial function and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group, and the difference was statistically significant (P＜0.05).There were no significant differences in the levels of superoxide dismutase (SOD), propylene glycol (MDA), left ventricular ejection fraction(LVEF), resistin, endothelin-1 (ET-1) and calcitonin gene-related peptide (CGRP) between the two groups before treatment (P＞0.05).After treatment, SOD, LVEF and CGRP levels in the two groups were higher than those before treatment,and observation group was higher than control group,the differences were statistically significant(P＜0.05).After treatment,the levels of resistin,ET-1 and MDA in the two groups were lower than those before treatment,and the observation group was lower than the control group, the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion The treatment of CHF patients with Sacubitril Valsartan Sodium Tablets combined with Spironolactone has relatively good efficacy, which can effectively improve cardiac function, vascular endothelial function and oxidative stress and with certain safety.

Key words： Chronic heart failure Sacurabatril Valsartan Sodium Spironolactone Oxidative stress Vascular endothelial function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Wen
	ZHANG Yuan-ya
	LI Dong-fang
	LIAO Ling
	LIU Fan

Cite this article:

ZHENG Wen,ZHANG Yuan-ya,LI Dong-fang, et al. Effect of Sacubatril Valsartan Sodium Tablets combined with Spironolactone on oxidative stress and vascular endothelial function in patients with chronic heart failure[J]. 中国当代医药, 2021, 28(8): 45-47转51.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I8/45

[1]	靳海斌.慢性心力衰竭的神经调节治疗及沙库巴曲缬沙坦钠应用新进展[J].心血管病学进展，2019，40（2）：283-286.
[2]	刘宁，刘昊，黄宇玲，等.ACEI 联合丹红注射液对慢性心衰合并心律失常的影响[J].中西医结合心脑血管病杂志，2017，15（3）：338-340.
[3]	高扬，栾波，高尧，等.沙库巴曲/缬沙坦治疗慢性心力衰竭的临床观察[J].中国循证心血管医学杂志，2019，11（5）：595-597.
[4]	于虹，赵天淼，刘凯.沙库巴曲缬沙坦钠片治疗老年慢性心力衰竭的效果[J].中国老年学杂志，2019，39（15）：3620-3622.
[5]	范剑峰，方译，郑春华.沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床疗效分析[J].中国临床药理学与治疗学，2019，24（7）：810-814.
[6]	中华医学会心血管病学分会.2014 中国心力衰竭诊断和治疗指南[J].中华心血管病杂志，2014，42（2）：98-122.
[7]	廖桂华，梁国君.沙库巴曲缬沙坦钠片联合卡维地洛治疗老年慢性心力衰竭的临床疗效[J].医学综述，2019，25（20）：4139-4143.
[8]	陈军红，李东野，徐通达，等.三维超声评价沙库巴曲缬沙坦治疗慢性心力衰竭疗效的研究[J].心肺血管病杂志，2019，38（3）：279-283.
[9]	张黎黎，石娅妮.沙库巴曲缬沙坦对老年慢性心力衰竭患者的疗效[J].西北药学杂志，2019，34（5）：680-683.
[10]	贾红丹，丛洪良，赵云凤，等.沙库巴曲缬沙坦治疗慢性心力衰竭患者的疗效观察[J].天津医药，2019，47（10）：1076-1080.
[11]	牛潇玉，赵晓燕.沙库巴曲缬沙坦及培哚普利治疗慢性心力衰竭的疗效对比[J].重庆医学，2019，48（11）：1874-1877.
[12]	刘焰华，李枫，汪蛟龙，等.沙库巴曲缬沙坦治疗慢性心力衰竭[J].长春中医药大学学报，2019，35（3）：457-460.
[13]	张清.多巴胺联合多巴酚丁胺治疗慢性心力衰竭合并肾功能不全的效果观察[J].中国当代医药，2018，25（5）：135-137.
[14]	李文波.沙库巴曲缬沙坦钠治疗慢性心力衰竭的效果[J].中国当代医药，2020，27（3）：91-93.
[15]	刘岳，汪芳.沙库巴曲缬沙坦的药代动力学和药效学特点[J].中国循环杂志，2018，33（2）：198-200.
[16]	陈升强.沙库巴曲缬沙坦钠联合卡维地洛对慢性心力衰竭的疗效研究[J].中国医药科学，2019，9（22）：69-71，105.
[17]	孟翠珍.沙库巴曲缬沙坦钠在慢性心力衰竭治疗中的临床疗效分析[J].山西医药杂志，2018，47（24）：2997-2998.